593 related articles for article (PubMed ID: 28319070)
21. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.
Beltran H; Rickman DS; Park K; Chae SS; Sboner A; MacDonald TY; Wang Y; Sheikh KL; Terry S; Tagawa ST; Dhir R; Nelson JB; de la Taille A; Allory Y; Gerstein MB; Perner S; Pienta KJ; Chinnaiyan AM; Wang Y; Collins CC; Gleave ME; Demichelis F; Nanus DM; Rubin MA
Cancer Discov; 2011 Nov; 1(6):487-95. PubMed ID: 22389870
[TBL] [Abstract][Full Text] [Related]
23. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
24. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
Lee AR; Gan Y; Tang Y; Dong X
EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
[TBL] [Abstract][Full Text] [Related]
25. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.
Mosquera JM; Beltran H; Park K; MacDonald TY; Robinson BD; Tagawa ST; Perner S; Bismar TA; Erbersdobler A; Dhir R; Nelson JB; Nanus DM; Rubin MA
Neoplasia; 2013 Jan; 15(1):1-10. PubMed ID: 23358695
[TBL] [Abstract][Full Text] [Related]
26. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
[TBL] [Abstract][Full Text] [Related]
27. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC.
Lee CF; Chen YA; Hernandez E; Pong RC; Ma S; Hofstad M; Kapur P; Zhau H; Chung LW; Lai CH; Lin H; Lee MS; Raj GV; Hsieh JT
Clin Transl Med; 2022 Feb; 12(2):e695. PubMed ID: 35184376
[TBL] [Abstract][Full Text] [Related]
28. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J
J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820
[TBL] [Abstract][Full Text] [Related]
29. Selective Actionable and Druggable Protein Kinases Drive the Progression of Neuroendocrine Prostate Cancer.
Lu C; Qie Y; Liu S; Wu C; Zhang Z; Liu R; Yang K; Hu H; Xu Y
DNA Cell Biol; 2018 Sep; 37(9):758-766. PubMed ID: 29969286
[TBL] [Abstract][Full Text] [Related]
30. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
[TBL] [Abstract][Full Text] [Related]
31. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine differentiation in prostate cancer: novel morphological insights and future therapeutic perspectives.
Santoni M; Conti A; Burattini L; Berardi R; Scarpelli M; Cheng L; Lopez-Beltran A; Cascinu S; Montironi R
Biochim Biophys Acta; 2014 Dec; 1846(2):630-7. PubMed ID: 25450825
[TBL] [Abstract][Full Text] [Related]
33. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells.
Lee JK; Phillips JW; Smith BA; Park JW; Stoyanova T; McCaffrey EF; Baertsch R; Sokolov A; Meyerowitz JG; Mathis C; Cheng D; Stuart JM; Shokat KM; Gustafson WC; Huang J; Witte ON
Cancer Cell; 2016 Apr; 29(4):536-547. PubMed ID: 27050099
[TBL] [Abstract][Full Text] [Related]
34. Definition of a FoxA1 Cistrome that is crucial for G1 to S-phase cell-cycle transit in castration-resistant prostate cancer.
Zhang C; Wang L; Wu D; Chen H; Chen Z; Thomas-Ahner JM; Zynger DL; Eeckhoute J; Yu J; Luo J; Brown M; Clinton SK; Nephew KP; Huang TH; Li W; Wang Q
Cancer Res; 2011 Nov; 71(21):6738-6748. PubMed ID: 21900400
[TBL] [Abstract][Full Text] [Related]
35. LIN28B promotes the development of neuroendocrine prostate cancer.
Lovnicki J; Gan Y; Feng T; Li Y; Xie N; Ho CH; Lee AR; Chen X; Nappi L; Han B; Fazli L; Huang J; Gleave ME; Dong X
J Clin Invest; 2020 Oct; 130(10):5338-5348. PubMed ID: 32634132
[TBL] [Abstract][Full Text] [Related]
36. Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
Wang J; Li J; Yin L; Pu T; Wei J; Karthikeyan V; Lin TP; Gao AC; Wu BJ
Oncogene; 2022 Sep; 41(37):4307-4317. PubMed ID: 35986103
[TBL] [Abstract][Full Text] [Related]
37. Molecular events in neuroendocrine prostate cancer development.
Wang Y; Wang Y; Ci X; Choi SYC; Crea F; Lin D; Wang Y
Nat Rev Urol; 2021 Oct; 18(10):581-596. PubMed ID: 34290447
[TBL] [Abstract][Full Text] [Related]
38. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
[TBL] [Abstract][Full Text] [Related]
39. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X
Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466
[TBL] [Abstract][Full Text] [Related]
40. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells.
Gupta A; Wang Y; Browne C; Kim S; Case T; Paul M; Wills ML; Matusik RJ
Prostate; 2008 Jan; 68(1):50-60. PubMed ID: 18004726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]